Researchers from the University Medical Centre in Ljubljana, Slovenia have found that in patients with elevated ST-segment myocardial infarction (MI), administering abciximab before primary angioplasty partially restores epicardial patency and helps resolve ST-segment elevation more rapidly.
A total of 163 patients with ST-segment elevation MI were randomly allocated to abciximab (administered as an immediate bolus of 0.25mg/kg followed by a 12 hour infusion of 0.125mcg/kg per minute) either before or after angioplasty or to no abciximab.
The results found: – After angioplasty, 70% of patients who were administered abciximab prior to the procedure experienced complete ST-segment resolution, compared to 36% of the patients who received abciximab after angioplasty and 37% of patients who did not receive abciximab at all. – A greater number of in-hospital complications were seen in the groups of patients who received abciximab after angioplasty or did not receive it. – These 2 groups of patients also had a higher mortality rate that was still apparent after 6 months compared to those pretreated with abciximab.
e-Med Tools
קצר קולע וממוקד
e-Med סמינרים
אי-מד תחקירים
Medscape Tools
Journal Club
מרכזי מידע ושירות
Facebook
מידע למפרסם
מאגר תרופות
מאגר אנשי המקצוע
אינדקס שימושי
חדשות משה"ב
eMed HealthClub
מחקרים קליניים
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!